How to Buy a Pharmacy: The Complete Acquisition Guide

Why Independent Pharmacies Are Strong Acquisition Targets

Independent pharmacies occupy a unique position in healthcare services acquisitions. Chain pharmacy dominance has not destroyed the independent sector — it has concentrated it among the pharmacies that chains cannot replicate: community-embedded, medically complex patient care, long-term care facility contracts, and compounding services that large operations are ill-equipped to provide.

**Prescription revenue is non-discretionary and insurer-backed.** Patients filling prescriptions for chronic conditions — diabetes, hypertension, cardiovascular disease, thyroid disorders — refill monthly, indefinitely, and through insurance that covers most of the cost. This is as close to contractually recurring revenue as exists in retail healthcare. The stickiness of a pharmacy patient base is among the highest of any healthcare business category.

**Long-term care contracts create institutional revenue.** Independent pharmacies serving nursing homes, assisted living facilities, and group homes under long-term care pharmacy contracts have a revenue anchor that is institutional rather than retail. A pharmacy with 3–5 long-term care facility contracts has a revenue floor that survives any individual patient attrition.

**Compounding pharmacies command premium valuations.** Independent pharmacies with FDA-registered or state-accredited compounding operations serve patients whose medications cannot be filled by chain pharmacies — custom hormone therapies, pediatric formulations, veterinary compounds, dermatology preparations. Compounding revenue typically carries higher margins than retail prescription dispensing and attracts a patient base that is not comparison-shopping on price.

**Aging owner demographics create motivated sellers.** The average independent pharmacy owner is in their mid-50s to mid-60s. Many have been operating for 20–30 years and have never seriously thought about the value of what they've built. When they decide to retire, the buyer pool is thin — most licensed pharmacists who could operate the business lack the capital to buy it without SBA financing, and most financial buyers don't understand the regulatory environment. Buyers who arrive prepared and credentialed find minimal competition.

For the full independent pharmacy acquisition market overview, the independent pharmacy acquisition guide covers deal structures, buyer expectations, and what lenders want to see.

Pharmacy Valuation: What Independent Pharmacies Are Worth

Independent pharmacies are valued on EBITDA multiples, with the multiple driven by revenue quality, PBM contract status, patient retention characteristics, and whether the pharmacy has services that chains don't offer.

The typical EBITDA multiple range for independent pharmacies is **3.0–6.0x**, with the spread driven by the following:

**Prescription dispensing volume and growth trend.** Prescriptions per day (Rxs/day) is the fundamental productivity metric. A pharmacy filling 150–200 Rxs/day has a different revenue profile than one filling 80 Rxs/day. More important than absolute volume is the trend — a pharmacy growing at 3–5% annually is worth more than a flat or declining pharmacy of the same current size.

**PBM contract status and reimbursement rates.** Pharmacy Benefit Manager (PBM) contracts — with CVS Caremark, Express Scripts, OptumRx, and others — determine what the pharmacy is paid for each prescription. In-network status with major PBMs is a prerequisite for maintaining prescription volume; patients covered by employer-sponsored insurance are typically required to use in-network pharmacies. Confirm in-network status with every PBM and review the reimbursement rate schedule before modeling any valuation.

**Long-term care facility contracts.** LTC pharmacy contracts are the highest-value revenue components in independent pharmacy acquisitions. An LTC contract with a 100-bed nursing facility generating $40K–$80K in monthly prescription revenue is worth significantly more than an equivalent dollar amount of retail walk-in volume — because the institutional relationship is far more durable.

**Specialty services: compounding, MTM, immunizations.** Compounding operations, medication therapy management (MTM) programs, and immunization programs diversify revenue and create services that chains do not replicate. These capabilities command multiple premiums of 0.5–1.0x over equivalent-EBITDA pharmacies without them.

**Front-end retail contribution.** Most independent pharmacies generate 15–25% of revenue from OTC products, health and beauty, and front-end merchandise. This revenue is lower-margin than prescription dispensing but adds to total store productivity and patient visit frequency.

Run your adjusted EBITDA through the EBITDA Valuation Estimator using healthcare retail or pharmacy sector comparables before setting or accepting any asking price.

• LTC contracts, compounding operation, 150+ Rxs/day, growing volume: 5.0–6.0x EBITDA
• Strong retail base, multiple PBM contracts, established community: 4.0–5.0x EBITDA
• Independent retail, 80–150 Rxs/day, limited specialty services: 3.0–4.0x EBITDA
• Declining volume, PBM reimbursement pressure, aging patient base: 2.5–3.0x EBITDA

Licensing and Regulatory Requirements

Pharmacy acquisitions are among the most heavily regulated small business transactions. The regulatory requirements must be understood and planned for before you make any offer.

**State pharmacy license.** Every pharmacy operates under a state Board of Pharmacy license issued to the specific location. A change of ownership requires notification to the state Board and typically requires the incoming pharmacist-owner or pharmacist-in-charge (PIC) to apply for a new license or transfer of ownership. Some states require a temporary permit during the transition. Contact your state Board of Pharmacy to understand the specific process and timeline before you structure any deal.

**DEA registration.** Pharmacies dispensing controlled substances — which is effectively all retail pharmacies — hold a DEA registration. A change of ownership requires notification to the DEA and a new DEA registration for the new owner. The DEA process typically takes 4–8 weeks after submission of the application. Dispensing controlled substances under the prior owner's DEA registration after a change of ownership is a federal violation. Build the DEA timeline into your closing schedule.

**PBM re-credentialing.** Every PBM contract requires notification of a change of ownership and re-credentialing of the pharmacy under the new owner. This process varies by PBM but typically takes 30–90 days. During the re-credentialing period, the pharmacy may not be able to bill certain PBMs — a significant cash flow disruption if not planned for. Some PBM contracts require a new application and approval process rather than a simple notification.

**Medicare and Medicaid provider enrollment.** Pharmacies enrolled in Medicare Part D and state Medicaid programs must notify CMS and state Medicaid of a change of ownership. Provider enrollment under the new owner typically takes 60–120 days. Plan for billing continuity during this window — some buyers structure closings to use a temporary period under the existing enrollment while re-credentialing is completed.

**Pharmacist licensure in the buyer.** In most states, a pharmacy's owner or pharmacist-in-charge must be a licensed pharmacist in that state. Confirm that your license (or your designated PIC's license) is current and in good standing in the acquisition state before you proceed.

SBA Financing for Pharmacy Acquisitions

Independent pharmacy acquisitions are strong SBA 7(a) loan candidates. Consistent prescription revenue, documented patient bases, and physical inventory collateral provide lenders with a clear underwriting story.

For a $1.2M acquisition: $120K equity injection (10%), $1.08M SBA 7(a) loan over 10 years at ~10.5%. Monthly debt service: approximately $14,600. Against a pharmacy generating $230K+ in adjusted EBITDA, the DSCR is 1.32x — within SBA guidelines.

**Inventory is real collateral.** A pharmacy's prescription drug inventory — typically valued at $150K–$400K for a mid-size independent — is tangible collateral that SBA lenders include in their collateral analysis. Combined with any fixtures, equipment, and real estate, inventory-backed pharmacies often have better collateral coverage than pure service businesses of comparable size.

**PBM re-credentialing timing affects the closing structure.** SBA lenders will want a plan for maintaining billing continuity during the PBM re-credentialing period. Some deals include a brief post-close period where the seller remains the PIC of record for billing purposes while the new owner completes credentialing — a structure that requires careful legal drafting to implement compliantly.

**Seller notes are common.** Sellers carrying 10–20% of the purchase price as a subordinated note reduces the SBA loan amount and improves DSCR. Many retiring pharmacist-owners are willing to structure a note — particularly if it allows the deal to close at their target price.

**Work with SBA lenders who have pharmacy experience.** Not all SBA lenders are comfortable with pharmacy acquisitions. The inventory, PBM credentialing, DEA registration, and Board of Pharmacy licensing complexity require a lender who has closed pharmacy deals before. Ask specifically about recent pharmacy acquisition experience before you engage any lender.

Model your deal before any lender conversation. The SBA Loan Calculator shows your monthly payment, DSCR, and whether the pharmacy's cash flow supports your target price at current rates.

Due Diligence for Pharmacy Acquisitions

Pharmacy due diligence has regulatory and operational elements that standard acquisition checklists miss. These are the items that produce the most post-close surprises.

**Verify prescription volume with PMS data.** Request a pharmacy management system (PMS) export showing Rxs per day by month for the trailing 24 months. Do not rely on claimed Rx counts — the actual dispensing data shows volume trends, seasonal patterns, and any declines the seller's summary figures may not reflect.

**Audit PBM contracts and reimbursement rates.** Request the actual PBM contracts and the most recent remittance statements from each PBM. Confirm in-network status, reimbursement rates per drug category, and any audit findings or pending chargebacks. PBM reimbursement rate changes are the most significant financial risk in independent pharmacy — a DIR fee increase or network exclusion can reduce margins materially without any change in Rx volume.

**Review controlled substance compliance and DEA history.** Request the DEA audit history for the last 5 years and the biennial inventory records. Confirm that Schedule II handling procedures are documented and compliant. DEA compliance deficiencies create liability that can follow the pharmacy location.

**Assess the long-term care contracts.** For pharmacies with LTC relationships, request the actual facility contracts — term, renewal options, pricing, and assignment provisions. LTC contracts are high-value but sometimes relationship-dependent. Confirm whether the contract is with the facility or the facility operator, and whether a change of pharmacy ownership requires consent.

**Evaluate the patient base for concentration and age.** A patient base concentrated in elderly patients in declining health has higher natural attrition than a mixed-age patient base. Request the active patient count by age demographic and chronic medication category. Medicare Part D volume is relatively stable; cash-pay and commercially-insured volume is more sensitive to price and convenience.

For the broader healthcare due diligence framework, the healthcare business acquisition due diligence checklist covers billing compliance, provider enrollment, and regulatory review applicable across healthcare acquisitions.

Structuring the Offer and Managing the Transition

The pharmacy LOI needs to address the regulatory and patient relationship risks specific to this acquisition type.

**Build in PBM re-credentialing and DEA registration timelines.** The LOI should include an explicit closing condition that all PBM re-credentialing applications have been submitted and all DEA registration requirements have been initiated. Some deals use a two-step closing: legal transfer of ownership at an initial close, with the seller remaining pharmacist-in-charge for billing purposes during a defined transition period while new credentialing is completed.

**Address inventory valuation at close.** Pharmacy inventory value changes daily. Include a provision for inventory to be valued by physical count at close, with the purchase price adjusted for the difference between modeled inventory value and actual count. Specify who conducts the count and what pricing methodology applies.

**Negotiate a genuine transition period.** 90–180 days of seller availability for patient introductions, PBM transition support, LTC facility relationship handoffs, and regulatory compliance questions is standard and worth negotiating for. The seller's presence during re-credentialing is practically necessary — build it into the purchase agreement as a deliverable with defined hours and availability.

**Include a patient retention contingency for large LTC contracts.** If LTC contracts represent 30%+ of EBITDA, structure a holdback or earnout tied to those contracts surviving the transition. A facility operator who switches pharmacies in the 6 months following a change of ownership should trigger a purchase price adjustment — protect yourself for this risk explicitly.

When terms are agreed, generate the LOI immediately. The LOI Generator produces a complete Letter of Intent — including PBM re-credentialing provisions, inventory valuation clause, DEA transition requirements, and SBA financing contingency — in under two minutes.